Skip to main content

Table 1 Baseline characteristics by ACPA status

From: ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial

Characteristic

ACPA-positive (n = 310)

ACPA-negative (n = 121)

Group difference

Female (number; %)

208 (67%)

89 (74%)

P = 0.1932

RF positive (number; %)

244 (79%)

47 (39%)

P <0.0012

Age (years)

54.0 (46.0, 64.0)

55.0 (47.0, 62.0)

P = 0.6611

Disease duration (months)

2.00 (0.00, 5.00)

1.00 (0.00, 4.00)

P = 0.1063

Larsen score

7.50 (2.50, 21.25)*

4.50 (1.00, 9.50)

P <0.0013

DAS28

5.72 (4.91, 6.73)

5.96 (4.92, 6.85)

P = 0.3051

HAQ

1.62 (1.00, 2.12)

1.62 (1.12, 2.12)

P = 0.5953

EuroQol

0.60 (0.15, 0.68)

0.58 (0.08, 0.68)

P = 0.5523

SF-36 PCS

28.68 (23.24, 35.95)

28.70 (22.90, 35.56)

P = 0.7133

SF-36 MCS

38.64 (27.65, 53.71)

35.87 (25.37, 52.95)

P = 0.2173

  1. All data are median interquartile range (IQR) unless otherwise stated; 1 = t-test; 2 = chi-squared test; 3 = Wilcoxon signed-rank test; *baseline Larsen scores missing in two ACPA-positive patients. ACPA, anti-citrullinated protein antibody; DAS28, disease activity scores on a 28-joint count; HAQ, Health Assessment Questionnaire; MCS, mental component summary; PCS, physical component summary; RF, rheumatoid factor.